ENDRA Life Sciences (NDRA) Retained Earnings (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Retained Earnings for 11 consecutive years, with -$111.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 6.99% year-over-year to -$111.8 million; the TTM figure through Mar 2026 stood at -$111.8 million (down 6.99% YoY), while the FY2025 annual figure was $112.7 million, up 6.35% from the prior year.
• Retained Earnings retreated to -$111.8 million in Q1 2026 per NDRA's latest filing, from $112.7 million in the prior quarter.
• Across five years, Retained Earnings topped out at $112.7 million in Q4 2025 and bottomed at -$111.8 million in Q1 2026.
• Historically, Retained Earnings has averaged -$35.5 million across 5 years, with a median of -$84.8 million in 2023.
• Annual changes were most pronounced in 2023 — Retained Earnings sank 201.92% — and 2024, when it soared 221.23%.
• ENDRA Life Sciences' Retained Earnings stood at -$81.9 million in 2022, then surged by 219.19% to $97.6 million in 2023, then advanced by 8.62% to $106.0 million in 2024, then grew by 6.35% to $112.7 million in 2025, then slumped by 199.16% to -$111.8 million in 2026.
• Business Quant data shows NDRA's Retained Earnings at -$111.8 million in Q1 2026, $112.7 million in Q4 2025, and -$107.3 million in Q3 2025.